The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice
Open accessAbstract
Adiponectin has recently been shown to be a promising candidate for the treatment of obesity-associated metabolic syndromes. Replenishment of recombinant adiponectin in mice can decrease hyperglycemia, reverse insulin resistance, and cause sustained weight loss without affecting food intake. Here we report its potential roles in alcoholic and nonalcoholic fatty liver diseases in mice. Circulating concentrations of adiponectin decreased significantly following chronic consumption of high-fat ethanol-containing food. Delivery of recombinant adiponectin into these mice dramatically alleviated hepatomegaly and steatosis (fatty liver) and also significantly attenuated inflammation and the elevated levels of serum alanine aminotransferase. These therapeutic effects resulted partly from the ability of adiponectin to increase carnitine palmitoyltransferase I activity and enhance hepatic fatty acid oxidation, while it decreased the activities of two key enzymes involved in fatty acid synthesis, including acetyl-CoA carboxylase and fatty acid synthase. Furthermore, adiponectin treatment could suppress the hepatic production of TNF-alpha and plasma concentrations of this proinflammatory cytokine. Adiponectin was also effective in ameliorating hepatomegaly, steatosis, and alanine aminotransferase abnormality associated with nonalcoholic obese, ob/ob mice. These results demonstrate a novel mechanism of adiponectin action and suggest a potential clinical application of adiponectin and its agonists in the treatment of liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1595 · Cited by 3,133
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity
Hu, E., Liang, P., & Spiegelman, B. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10697 · Cited by 2,238
Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin
Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., et al. (1999) · Circulation · doi:10.1161/01.cir.100.25.2473 · Cited by 2,147
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et al. (2002) · Nature Medicine · doi:10.1038/nm724 · Cited by 2,088
Fruebis, J., Tsao, T., Javorschi, S., Ebbets-Reed, D., Erickson, M., Yen, F. T., Bihain, B. E., & Lodish, H. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041591798 · Cited by 1,985
Research works printed but not linked: 4
- Kubota, 2002, J. Biol. Chem., 277, 35863
- Wilkes, 1996, Am. J. Physiol., 271, E477
- Winder, 1999, Am. J. Physiol., 277, E1
- Funabiki, 2002, Diabetes., 51(Suppl. 2), 32a
Cited by
Items 101–154 of 154
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition
Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., & McClain, C. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.12.006 · Cited by 291
Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention
Zhu, W., Cheng, K. K. Y., Vanhoutte, P. M., Lam, K. S. L., & Xu, A. (2008) · Clinical Science · doi:10.1042/cs20070347 · Cited by 291
Self-citationBeneficial Effects of Betaine: A Comprehensive Review
Arumugam, M. K., Paal, M. C., Donohue, T. M., Ganesan, M., Osna, N. A., & Kharbanda, K. K. (2021) · Biology · doi:10.3390/biology10060456 · Cited by 291
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
Wu, X., Fan, X., Miyata, T., Kim, A., Cajigas-Du Ross, C. K., Ray, S., Huang, E., Taiwo, M., Arya, R., Wu, J., et al. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-030435 · Cited by 289
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 285
Lipocalin-2 Deficiency Attenuates Insulin Resistance Associated With Aging and Obesity
Law, I. K. M., Xu, A., Lam, K. S. L., Berger, T., Mak, T. W., Vanhoutte, P. M., Liu, J. T. C., Sweeney, G., Zhou, M., Yang, B., et al. (2010) · Diabetes · doi:10.2337/db09-1541 · Cited by 284
Self-citationQureshi, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i26.3540 · Cited by 283
Wong, G. W., Krawczyk, S. A., Kitidis‐Mitrokostas, C., Ge, G., Spooner, E., Hug, C., Gimeno, R., & Lodish, H. F. (2009) · The FASEB Journal · doi:10.1096/fj.08-114991 · Cited by 279
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Viollet, B. (2009) · Frontiers in Bioscience · doi:10.2741/3460 · Cited by 278
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Lin, Z., Pan, X., Wu, F., Ye, D., Zhang, Y., Wang, Y., Jin, L., Lian, Q., Huang, Y., Ding, H., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015308 · Cited by 271
Self-citationWang, Y., Lam, J. B., Lam, K. S. L., Liu, J., Lam, M. C., Hoo, R. L. C., Wu, D., Cooper, G. J. S., & Xu, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1969 · Cited by 270
Self-citationXu, A., Lam, M. C., Chan, K. W., Wang, Y., Zhang, J., Hoo, R. L. C., Xu, J. Y., Chen, B., Chow, W.-S., Tso, A. W. K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408452102 · Cited by 269
Self-citationFat in the liver and insulin resistance
Yki‐Järvinen, H. (2005) · Annals of Medicine · doi:10.1080/07853890510037383 · Cited by 268
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 264
Hypoadiponectinemia as a Predictor for the Development of Hypertension: A 5-Year Prospective Study
Chow, W.-S., Cheung, B. M. Y., Tso, A. W. K., Xu, A., Wat, N. M. S., Fong, C. H. Y., Ong, L. H. Y., Tam, S., Tan, K. C. B., Janus, E. D., et al. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.086835 · Cited by 264
Self-citationAdvances in Pediatric Nonalcoholic Fatty Liver Disease†
Loomba, R., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2009) · Hepatology · doi:10.1002/hep.23119 · Cited by 264
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
You, M., Considine, R. V., Leone, T. C., Kelly, D. P., & Crabb, D. W. (2005) · Hepatology · doi:10.1002/hep.20821 · Cited by 259
Molecular Mechanism for Adiponectin-dependent M2 Macrophage Polarization
Mandal, P., Pratt, B. T., Barnes, M., McMullen, M. R., & Nagy, L. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.204644 · Cited by 258
Lipid-Overloaded Enlarged Adipocytes Provoke Insulin Resistance Independent of Inflammation
Kim, J. I., Huh, J. Y., Sohn, J. H., Choe, S. S., Lee, Y. S., Lim, C. Y., Jo, A., Park, S. B., Han, W., & Kim, J. B. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01321-14 · Cited by 258
Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257
“ALT, U/L, mean ± SD 31 ± 25b 28 ± 11 31 ± 20d 34 ± 23 26 ± 10d 30 ± 17c ALT >44 U/L (men)e or >32 U/L (women)e, n (%) 4 (17) 5 (21) 4 (17) 8 (33) 3 (13) 20 (21)”
BackgroundPlasma adiponectin is decreased in nonalcoholic fatty liver disease
Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L. A., & Vettor, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01821 · Cited by 256
A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats
Svegliati-Baroni, G., Candelaresi, C., Saccomanno, S., Ferretti, G., Bachetti, T., Marzioni, M., De Minicis, S., Nobili, L., Salzano, R., Omenetti, A., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050953 · Cited by 256
Wang, Y., Lam, K. S. L., Chan, L., Chan, K. W., Lam, J. B. B., Lam, M. C., Hoo, R. C. L., Mak, W. W. N., Cooper, G. J. S., & Xu, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513907200 · Cited by 256
Self-citationTilg, H., & Moschen, A. R. (2008) · Clinical Science · doi:10.1042/cs20070196 · Cited by 252
Induction of Adiponectin in Skeletal Muscle by Inflammatory Cytokines: in Vivo and in Vitro Studies
Delaigle, A. M., Jonas, J.-C., Bauche, I. B., Cornu, O., & Brichard, S. M. (2004) · Endocrinology · doi:10.1210/en.2004-0503 · Cited by 241
Chen, B., Lam, K. S. L., Wang, Y., Wu, D., Lam, M. C., Shen, J., Wong, L., Hoo, R. L. C., Zhang, J., & Xu, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.004 · Cited by 238
Self-citationNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease
Sanyal, A. J. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0084 · Cited by 216
“NAFLD is associated with decreased expression of adiponectin, a PPAR-γ sensitive cytokine that can reverse the pathologic features of NAFLD in animal models of the disease”
BackgroundPaniagua, J. A. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i19.483 · Cited by 197
Parimisetty, A., Dorsemans, A.-C., Awada, R., Ravanan, P., Diotel, N., & Lefebvre d’Hellencourt, C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0530-x · Cited by 188
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“and hence interfering with the direct effects of insulin on liver glucose metabolism 105–107 .”
Hajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128
“NAFLD is associated with insulin resistance and increased triglyceride levels,(39-41) decreased adiponectin levels,(42-45) and metabolic syndrome.”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Saponaro, C., Sabatini, S., Gaggini, M., Carli, F., Rosso, C., Positano, V., Armandi, A., Caviglia, G. P., Faletti, R., Bugianesi, E., et al. (2022) · Liver International · doi:10.1111/liv.15377 · Cited by 116
The role of vitamin D and vitamin D binding protein in chronic liver diseases
Pop, T. L., Sîrbe, C., Benţa, G., Mititelu, A., & Grama, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810705 · Cited by 105
“Vitamin D promotes adiponectin secretion in cultured adipocytes, and adiponectin has antiinflammatory and insulin-sensitizing properties [84] and, together with VDR, is involved in the homeostasis of the other organs linked to MAFLD (gut and adipose tissue) [62].”
BackgroundAdiponectin: Protection of the endothelium
Lam, K. S. L., & Xu, A. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0019-y · Cited by 94
Self-citationThe pathophysiology of abdominal adipose tissue depots in health and disease
Walker, G. E., Marzullo, P., Ricotti, R., Bona, G., & Prodam, F. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0023 · Cited by 90
Cernkovich, E. R., Deng, J., Bond, M. C., Combs, T. P., & Harp, J. B. (2008) · Endocrinology · doi:10.1210/en.2007-1148 · Cited by 87
Induction of adiponectin in skeletal muscle of type 2 diabetic mice: In vivo and in vitro studies
Delaigle, A. M., Senou, M., Guiot, Y., Many, M. C., & Brichard, S. M. (2006) · Diabetologia · doi:10.1007/s00125-006-0210-y · Cited by 79
Ahmad, A., Ali, T., Kim, M. W., Khan, A., Jo, M. H., Rehman, S. U., Khan, M. S., Abid, N. B., Khan, M., Ullah, R., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.004 · Cited by 76
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.001 · Cited by 74
Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M., Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab624 · Cited by 72
Uncoupling Proteins: Role in Insulin Resistance and Insulin Insufficiency
B.Chan, C., & Harper, M.-E. (2006) · Current Diabetes Reviews · doi:10.2174/157339906777950660 · Cited by 71
Adiponectin: a key fat-derived molecule regulating inflammation
Tilg, H., & Wolf, A. M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.245 · Cited by 71
“recently demonstrated a beneficial effect of adiponectin on alcoholic and non-alcoholic fatty liver disease in mice [44].”
BackgroundNovel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
Filip, R., Radzki, R., & Bieńko, M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s170533 · Cited by 60
Park, P.-H., Huang, H., McMullen, M. R., Bryan, K., & Nagy, L. E. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907631 · Cited by 53
(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Takahashi, T., Saegusa, S., Sumino, H., Nakahashi, T., Iwai, K., Morimoto, S., & Kanda, T. (2005) · Journal of International Medical Research · doi:10.1177/147323000503300208 · Cited by 33
Adiponectin downregulates TNF-α expression in degenerated intervertebral discs
Yuan, B., Huang, L., Yan, M., Zhang, S., Zhang, Y., Jin, B., Ma, Y., & Luo, Z. (2018) · Spine · doi:10.1097/brs.0000000000002364 · Cited by 30
Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators
Serhal, R., Hilal, G., Boutros, G., Sidaoui, J., Wardi, L., Ezzeddine, S., & Alaaeddine, N. (2015) · BioMed Research International · doi:10.1155/2015/850246 · Cited by 18
Varmazyar, I., Monazzami, A. A., Moradi, M., & McAinch, A. J. (2024) · BMC Sports Science, Medicine and Rehabilitation · doi:10.1186/s13102-024-00972-9 · Cited by 7
Metadata
- Authors
- Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-07-01
- Volume
- 112
- Issue
- 1
- Pages
- 91-100
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2120590109
- Cited by
- 1,296
- References
- 68
- FWCI
- 47.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.